skip to Main Content
IRBM Publishes On Optimizing A New Series Of Trypanosoma Brucei Growth Inhibitors, The Parasite Responsible Of The Sleeping Sickness

IRBM publishes on optimizing a new series of Trypanosoma brucei growth inhibitors, the parasite responsible of the sleeping sickness

Human African trypanosomiasis (HAT), also known as sleeping sickness, is a parasitic disease that causes significant mortality in sub- Saharan Africa. A previous publication from IRBM laboratory reported the identification of 2-(1H-imidazo-2-yl)piperazines as a new series of potent T. brucei growth inhibitors.
IRBM’s Publishes In Cells On Establishing A Human Blood-brain Barrier Model For Use In Drug Discovery For Neurodegenerative Diseases Such As Huntington’s

IRBM’s publishes in Cells on establishing a human blood-brain barrier model for use in drug discovery for neurodegenerative diseases such as Huntington’s

The blood-brain barrier (BBB) is responsible for the homeostasis between the cerebral vasculature and the brain. It has a key role in regulating the influx and efflux of substances, in healthy and diseased states. Stem cell technology offers the opportunity to use human brain-specific cells to establish in vitro BBB models.

IRBM contribution to Frontiers in Neuroscience

In an original research publication for the current issue of Frontiers in Neuroscience, IRBM and collaborators developed and applied novel ultrasensitive immunoassays to enable detection of synuclein and S129 phosphorylated synuclein in clinical samples. The new research demonstrated that S129…

New IRBM contribution to Metabolites

As part of a special issue on exercise metabonomics, IRBM recently published a paper in Metabolites exploring the limits and advantages of using saliva to observe metabolic responses to physical exercise. Saliva offers a number of advantages over traditional blood…

Back To Top